SOPHiA GENETICS (NASDAQ:SOPH) President Sells $13,484.24 in Stock

Key Points

• President Ross Muken sold shares: Muken executed a Rule 10b5-1 sale (2,786 shares on Apr 8 at $4.84) as part of multiple recent dispositions totaling 8,343 shares for roughly $40.2K, reducing his stake by about 0.40% to 695,311 shares to cover tax withholding on vested awards.
• Company fundamentals and analyst view: SOPH trades near $4.70 with a market cap of ~$322M, reported a quarterly EPS miss (‑$0.28 vs. est. ‑$0.20) and negative margins, while analysts show mixed views (consensus "Hold" with a $7.00 price target and a split of Buy/Sell ratings).
• Market flows are mixed: several institutional investors added small positions in recent quarters (institutional ownership ~31.6%), but short interest rose ~20% in late March to about 255k shares (~0.4% of float), which could add near‑term volatility.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) President Ross Muken sold 2,786 shares of SOPHiA GENETICS stock in a transaction dated Wednesday, April 8th. The shares were sold at an average price of $4.84, for a total transaction of $13,484.24. Following the sale, the president owned 695,311 shares in the company, valued at approximately $3,365,305.24. This trade represents a 0.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ross Muken also recently made the following trade(s):

• On Thursday, April 9th, Ross Muken sold 1,950 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.74, for a total transaction of $9,243.00.
• On Tuesday, April 7th, Ross Muken sold 2,424 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.87, for a total transaction of $11,804.88.
• On Thursday, March 19th, Ross Muken sold 1,183 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.79, for a total transaction of $5,666.57.

SOPHiA GENETICS Price Performance

NASDAQ:SOPH traded down $0.03 on Friday, reaching $4.70. The stock had a trading volume of 94,702 shares, compared to its average volume of 184,971. The company has a market capitalization of $321.90 million, a P/E ratio of -9.22 and a beta of 1.04. SOPHiA GENETICS SA has a 1-year low of $2.58 and a 1-year high of $5.70. The company has a quick ratio of 1.84, a current ratio of 1.96 and a debt-to-equity ratio of 1.01. The stock has a fifty day moving average price of $4.76 and a 200-day moving average price of $4.68.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last released its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.08). The firm had revenue of $21.71 million during the quarter, compared to analyst estimates of $21.20 million. SOPHiA GENETICS had a negative net margin of 44.22% and a negative return on equity of 50.60%. Research analysts forecast that SOPHiA GENETICS SA will post -0.96 EPS for the current year.

Hedge Funds Weigh In On SOPHiA GENETICS

Institutional investors have recently modified their holdings of the stock. Savvy Advisors Inc. bought a new position in shares of SOPHiA GENETICS in the third quarter worth about $48,000. Squarepoint Ops LLC bought a new position in shares of SOPHiA GENETICS in the third quarter worth about $49,000. Perkins Capital Management Inc. bought a new position in shares of SOPHiA GENETICS in the fourth quarter worth about $49,000. Quadrature Capital Ltd bought a new position in shares of SOPHiA GENETICS in the fourth quarter worth about $54,000. Finally, XTX Topco Ltd bought a new position in shares of SOPHiA GENETICS in the fourth quarter worth about $55,000. 31.59% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on SOPH shares. BTIG Research restated a "buy" rating and issued a $7.00 price target on shares of SOPHiA GENETICS in a research report on Tuesday, March 3rd. Weiss Ratings restated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research report on Thursday, January 22nd. Finally, Guggenheim boosted their price target on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the company a "buy" rating in a research report on Monday, January 26th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $7.00.

SOPHiA GENETICS News Summary

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Large institutional accumulation — UBS, Akre and several other funds materially increased positions in recent quarters, signaling conviction from some large investors which could provide demand support for the stock.
• Positive Sentiment: Analyst upside — Guggenheim and BTIG have issued Buy ratings and target prices around $7, above the current trading level, giving the stock upside on positive research momentum.
• Neutral Sentiment: Multiple executives sold small blocks of shares under pre‑arranged Rule 10b5‑1 plans to cover tax withholding associated with vested awards; these are routine and reduce the informational signal from insider sales. Representative SEC filing for CEO sales. CEO Form 4
• Neutral Sentiment: Additional planned sales by other insiders (CFO, President, CTO and others) were disclosed; most trades are modest relative to executive holdings and were executed under 10b5‑1 plans — still worth monitoring for short‑term supply impact. Example coverage of a recent insider sale. InsiderTrades article
• Negative Sentiment: Short interest increased ~20% in late March to ~255k shares (≈0.4% of float), raising potential downward pressure and the possibility of elevated volatility if shorts add to positions or cover into thin trading days.
• Negative Sentiment: Recent fundamentals remain challenged — SOPH reported an EPS miss in early March and continues to show negative margins and ROE; analysts still model negative EPS for the year, which keeps valuation sensitivity high.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.